Archana Shrestha

Dr. Archana Shrestha

Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ASArchana Shrestha
Archana Shrestha
BLBehnaz Lahooti
Behnaz Lahooti
CMConstantinos M. Mikelis
Constantinos M. Mikelis
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis
In the generational evolution of nano-based drug delivery carriers, active targeting has been a major milestone for improved and selective drug accumulation in tissues and cell types beyond the existing passive targeting capabilities. Among the various active targeting moieties, chlorotoxin, a peptide extracted from scorpions, demonstrated promising tumor cell accumulation and selection. With lung cancer being among the leading diagnoses of cancer-related deaths in both men and women, novel therapeutic methodologies utilizing nanotechnology for drug delivery emerged. Given chlorotoxin’s promising biological activity, we explore its potential against lung cancer and its utilization for active targeting against this cancer’s tumor cells. Our analysis indicates that despite the extensive chlorotoxin’s research against glioblastoma, lung cancer research with the molecule has been limited, despite some promising early results.

12 June 2023 in Processes
Verified
Journal Article
Open access
PDF file
ASArchana Shrestha
Archana Shrestha
MHMD ANAMUL HAQUE
MD ANAMUL HAQUE
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis
Administration through the respiratory tract can be advantageous, with high drug bioavailability, limited enzymatic activity, reduced dose requirements compared to oral, and potentially diminished side effects. Among the different types of drugs studied for pulmonary delivery, genetic material delivery has gained favorable scientific interest, using polymer-, lipid-, inorganic-, or vector-based nanocarriers. As pulmonary drug delivery has been associated with challenges, including physiological barriers and lung metabolism, the delivery of sensitive molecules such as nucleic acids can exacerbate these challenges. While short-interfering RNAs (siRNAs) have been extensively reported as suitable ribonucleic acid interference (RNAi) candidates for pulmonary delivery, discussion on micro-RNA (miR) pulmonary delivery is limited despite their significant therapeutic potential. Recently, these non-coding RNAs have been explored in targeted or non-targeted pulmonary administration against various diseases. This review addresses the information gap on miR-pulmonary delivery with updated and concentrated literature. We briefly discuss the barriers to lung administration, describe different functional nanocarriers for miR delivery, and provide an extensive literature update on the different miRs and their targeted diseases currently being studied.

5 August 2025 in Processes
Verified
Journal Article
Open access
PDF file
MHMD ANAMUL HAQUE
MD ANAMUL HAQUE
ASArchana Shrestha
Archana Shrestha
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis
Lipid nanoparticle (LNP)-based delivery systems are promising tools for advancing RNA-based therapies. However, there are underlying challenges for the oral delivery of LNPs. In this study, we optimized an LNP formulation, which we encapsulated in a pH-sensitive Eudragit® S 100 (Eu) coating. LNPs were prepared using the DLin-MC3-DMA ionizable lipid, cholesterol, DMG-PEG, and DSPC at a molar ratio of 50:38.5:10:1.5. LNPs were coated with 1% Eu solution via nanoprecipitation using 0.25% acetic acid to get Eu-coated LNPs (Eu-LNPs). Particle characteristics of LNPs were determined by using dynamic light scattering (DLS). Ribogreen and agarose gel retardation assays were used to evaluate nucleic acid entrapment and stability. LNPs and Eu-LNPs were ~120 nm and 4.5 μm in size, respectively. Eu-LNPs decrease to an average size of ~191 ± 22.9 nm at a pH of 8. Phosphate buffer (PB)-treated and untreated Eu-LNPs and uncoated LNPs were transfected in HEK-293 cells. PB-treated Eu-LNPs showed significant transfection capability compared to their non-PB-treated counterparts. Eu-LNPs protected their nucleic acid payloads in the presence of a simulated gastric fluid (SGF) with pepsin and maintained transfection capacity following SGF or simulated intestinal fluid. Hence, Eu coating is a potentially promising approach for the oral administration of LNPs.

Verified
Journal Article
Open access
PDF file
ASArchana Shrestha
Archana Shrestha
BLBehnaz Lahooti
Behnaz Lahooti
AHA. K. M. Nawshad Hossian
A. K. M. Nawshad Hossian
MMMahboubeh Madadi
Mahboubeh Madadi
CMConstantinos M. Mikelis
Constantinos M. Mikelis
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis
The mainstays of lung cancer pathogenesis are cell cycle progression dysregulation, impaired apoptosis, and unregulated cell proliferation. While individual microRNA (miR) targeting or delivering is a promising approach that has been extensively studied, combination of miR targeting can enhance therapeutic efficacy and overcome limitations present in individual miR regulations. We previously reported on the use of a miR-143 and miR-506 combination via transient transfections against lung cancer. In this study, we evaluated the effect of miR-143 and miR-506 under stable deregulations in A549 lung cancer cells. We used lentiviral transductions to either up- or downregulate the two miRs individually or in combination. The cells were sorted and analyzed for miR deregulation via qPCR. We determined the miR deregulations’ effects on the cell cycle, cell proliferation, cancer cell morphology, and cell motility. Compared to the individual miR deregulations, the combined miR upregulation demonstrated a miR-expression-dependent G2 cell cycle arrest and a significant increase in the cell doubling time, whereas the miR-143/506 dual downregulation demonstrated increased cellular motility. Furthermore, the individual miR-143 and miR-506 up- and downregulations exhibited cellular responses lacking an apparent miR-expression-dependent response in the respective analyses. Our work here indicates that, unlike the individual miR upregulations, the combinatorial miR treatment remained advantageous, even under prolonged miR upregulation. Finally, our findings demonstrate potential advantages of miR combinations vs. individual miR treatments.

24 August 2025
Verified
Book Chapter
Closed access
PDF file
ASArchana Shrestha
Archana Shrestha
MHMD ANAMUL HAQUE
MD ANAMUL HAQUE
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis

7 January 2026 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
BBBipana Basnet
Bipana Basnet
Anup LuitelAnup Luitel
Anup Luitel
RSRajan Shrestha
Rajan Shrestha
PSPrajesh Shrestha
Prajesh Shrestha
ASArchana Shrestha
Archana Shrestha
LPLalit Mohan Pant
Lalit Mohan Pant
Objective: The present study aimed to formulate and evaluate bilayer tablets containing sustained-release Metformin hydrochloride and immediate-release Empagliflozin for the management of Type 2 diabetes. Methods: The wet granulation technique was employed to formulate a sustained-release Metformin HCl layer and an immediate-release Empagliflozin layer. The impact of varying concentrations of independent variables (HPMCK100M and Carbopol 971P) on drug release at different times was evaluated using a 2-factor central composite design (CCD)with five central replicates.The formulation was optimized using responsesurface methodology (RSM) through CCD, and optimal levels of polymers were determined using surface plots and response optimizer. In-vitro release data observed from the optimized formulation were subjected to pre- and post-compression analysis and fitted into various drug release kinetic models. Results: Using response surface methodology (RSM), the optimized formulation contained 17.9% HPMCK100M and 3.8% Carbopol, respectively. Various parameters were noted: hardness, 21.33kg/cm²; friability, 0.23%; and uniformity of content for empagliflozin (98.23%), whichwas within the limit.The assay percentages of metformin and empagliflozin were 95.27% and 96%, respectively. In vitro drug release at 1, 6, 10, and 12 hours is 20.08%, 67.02%, 87.06%, and 97.52%, respectively, which is comparable to the predicted drug release by RSM.The optimized model accurately predicted the drug release profile, with a chi-square test (χ² = 0.436, df = 3) and a similarity factor (f2) of 82.54showing no significant differences.Similarly, the drug release of the optimized formulation followed the Korsmeyer–Peppas model (R²= 0.9986), indicating a combination of diffusion and polymer relaxation mechanisms inthe drug release process. Conclusion: In conclusion, we developed an optimized fixed-dose bilayer formulation of sustained-release metformin HCl and immediate-release empagliflozin using a central composite design. The optimized formulation exhibited predictable release kinetics, best described by the Korsmeyer-Peppas model, confirming anomalous transport driven by both diffusion and polymer relaxation. This work presents how experimental design and mechanistic modeling can be integrated to aid in the development of bilayer tablet formulations, thereby validating the growing body of knowledge in this field. Clinically, the formulation presents a promising approach for improving glycemic control, enhancing patient compliance, and reducing healthcare costs.